MedTrace Logo

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

NCT05004025 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-08-15

No results posted yet for this study

Summary

Tumor Treating Fields targeted to liver metastases may improve outcomes for patients with metastatic uveal melanoma treated with immune checkpoint inhibitors.

Conditions

Interventions

DEVICE

Novocure Optune

Novacure Optune with Opdivo and Yervoy

DRUG

Opdivo

Novacure Optune with Opdivo and Yervoy

DRUG

Yervoy

Novacure Optune with Opdivo and Yervoy

Sponsors & Collaborators

  • NovoCure Ltd.

    collaborator INDUSTRY

  • HonorHealth Research Institute

    lead OTHER

Principal Investigators

  • Justin Moser, MD · HonorHealth Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2024-11-18
Completion
2025-07-23
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05004025 on ClinicalTrials.gov